Loading clinical trials...
Loading clinical trials...
Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Genzyme, a Sanofi Company
NCT06666413 · Glycogen Storage Disease Type II, Pompe's Disease
NCT04808505 · Glycogen Storage Disease Type II Infantile Onset
NCT07136844 · Neuromuscular Diseases, Obesity (Disorder), and more
NCT06616545 · Glycogen Storage Disease Type III
NCT03564561 · Glycogen Storage Disease Type II, Adult
University of Alabama
Birmingham, Alabama
Shands Hospital at the University of Florida
Gainesville, Florida
Miami Children's Hospital
Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions